早发冠心病患者高密度脂蛋白抗HUVEC凋亡的作用机制
DOI:
作者:
作者单位:

(1.山西医科大学,;2.山西医科大学第二医院心内科 心血管疾病诊治及临床药理山西省重点实验室,;3.山西医科大学第一医院心内科,山西省太原市 030001)

作者简介:

侯曜曜,硕士研究生,研究方向为冠心病的基础与临床,E-mail为985090433@qq.com。

通讯作者:

基金项目:


Mechanism of high density lipoprotein against HUVEC apoptosis in patients with premature coronary heart disease
Author:
Affiliation:

1.Shanxi Medical University, ;2.Department of Cardiology, the Second Hospital of Shanxi Medical University & Key Laboratory of Cardiovascular Disease Diagnosis, Treatment and Clinical Pharmacology of Shanxi Province, ;3.Department of Cardiology, the First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 通过细胞实验探究早发冠心病(PCHD)患者高密度脂蛋白(HDLPCHD)与健康人群HDL(HDLhealth)抗人脐静脉内皮细胞(HUVEC)凋亡作用是否有区别及其可能机制。 方法 采集PCHD患者和与之相匹配的健康人血样,并提取HDL;不同浓度氧化型低密度脂蛋白(ox-LDL)处理HUVEC 24 h,MTT检测细胞存活率,明确ox-LDL引起HUVEC凋亡的合适浓度;不同浓度、不同时间的HDLhealth预处理HUVEC后,再用合适浓度的ox-LDL处理HUVEC 24 h,MTT检测细胞存活率,明确HDLhealth预处理HUVEC的最适浓度与最适作用时间;用最适浓度HDLhealth、HDLPCHD对HUVEC进行最适作用时间的预处理,再用合适浓度的ox-LDL处理HUVEC 24 h,MTT检测细胞存活率。Annexin V-FITC/PI凋亡检测试剂盒进行流式细胞检测,Western blot检测Caspase 3、Caspase 9的蛋白表达,用试剂盒测定活性氧(ROS)活性,使用Lipoprint脂蛋白分析仪分析HDLhealth和HDLPCHD亚组分(HDL1-HDL10)分布情况。 结果 100 mg/L ox-LDL处理HUVEC 24 h后细胞存活率为60.34%,较空白处理组明显降低(P<0.05);200 mg/L HDLhealth预处理HUVEC 18 h后,细胞存活率为82.01%,可以明显减弱ox-LDL对细胞的损伤;200 mg/L HDLhealth显著抑制100 mg/L ox-LDL诱导的HUVEC凋亡及Caspase 3、Caspase 9的蛋白表达和ROS产生;200 mg/L HDLPCHD预处理HUVEC 18 h后,细胞存活率为65.5%,其作用较HDLhealth减弱;200 mg/L HDLPCHD可抑制100 mg/L ox-LDL诱导的HUVEC凋亡及Caspase 3、Caspase 9的蛋白表达和ROS产生,但作用较HDLhealth减弱;HDLPCHD亚组分大颗粒(HDL1-HDL3)含量较HDLhealth低(28.5%±5.7%比46.8%±15.2%),而小颗粒(HDL8-HDL10)含量较HDLhealth高(21.4%±7.8%比10.9%±5.4%)。 结论 HDLPCHD与HDLhealth比较,可能由于其亚组分大颗粒(HDL1-HDL3)含量较HDLhealth低,而小颗粒(HDL8-HDL10)含量较HDLhealth高,导致其抗氧化功能减弱,抑制ox-LDL诱导内皮细胞凋亡的功能亦减弱,从而减弱或丧失抗动脉粥样硬化的作用。

    Abstract:

    Aim To investigate whether there is a difference between HDLPCHD and HDLhealth against human umbilical vein endothelial cells apoptosis in patients with premature coronary heart disease (PCHD) and the possible mechanism. Methods Blood samples of PCHD patients and healthy subjects were collected, and HDL was isolated from the blood samples. Human umbilical vein endothelial cells were treated for 24 hours with different concentrations of oxidized low density lipoprotein (ox-LDL), cell viability was detected by MTT, to identify the appropriate concentration of ox-LDL induced human umbilical vein endothelial cells cell apoptosis. Human umbilical vein endothelial cells were pretreated with different hours and different concentration of HDLhealth, then treated with the appropriate concentration of ox-LDL for 24 hours, cell viability was detected by MTT, to identify the optimal concentration and time of HDLhealth pretreated human umbilical vein endothelial cells. Human umbilical vein endothelial cells were pretreated with the optimal hours and the optimal concentration of HDLhealth and HDLPCHD, then treated with the appropriate concentration of ox-LDL for 24 hours, cell viability was detected by MTT. Annexin V-FITC/PI apoptosis detection kit was used for flow cytometry staining, Western blot was used to detect Caspase 3 and Caspase 9 protein expression, kit was used to detect the activity of reactive oxygen species (ROS), sub-fraction (HDL1-HDL10) distribution of HDLhealth and HDLPCHD were analyzed by Lipoprint System. Results Human umbilical vein endothelial cell survival rate was 60.34% after treatmented with 100 mg/L ox-LDL for 24 hours, which was significantly lower than that in the blank treatment group (P<0.05). Human umbilical vein endothelial cell survival rate was 82.01% after pretreated with 200 mg/L HDLhealth for 18 hours, which could significantly reduce the damage of ox-LDL to cells. 200 mg/L HDLhealth could significantly inhibit apoptosis of human umbilical vein endothelial cells, the expression of Caspase 3 and Caspase 9 and the production of ROS , which were induced by 100 mg/L ox-LDL. Human umbilical vein endothelial cell survival rate was 65.5% after pretreated with 200 mg/L HDLPCHD for 18 hours, and its effect was weaker than that of HDLhealth. 200 mg/L HDLPCHD could inhibit apoptosis of human umbilical vein endothelial cells, the expression of Caspase 3 and Caspase 9 and the production of ROS induced by 100 mg/L ox-LDL, but the effect was weaker than that of HDLhealth. The content of large particle (HDL1-HDL3) in HDLPCHD subgroup was lower than that in HDLhealth (28.5%±5.7% vs. 46.8%±15.2%), while the content of small particle (HDL8-HDL10) was higher than that of HDLhealth (21.4%±7.8% vs. 10.9%±5.4%). Conclusion Comparison to the HDLhealth, perhaps due to the large particle of HDLPCHD sub-fraction content (HDL1-HDL3) was lower than that of HDLhealth, while the small particle was higher than that of HDLhealth (HDL8-HDL10), resulting in antioxidant function weakened, inhibiting the apoptosis of endothelial cells induced by ox-LDL were decreased, thereby weakening or losing the role of anti-atherosclerosis.

    参考文献
    相似文献
    引证文献
引用本文

侯曜曜,尔璐,张永亮,宋晓苏,白瑞,梁斌,边云飞,肖传实.早发冠心病患者高密度脂蛋白抗HUVEC凋亡的作用机制[J].中国动脉硬化杂志,2017,25(7):671~678.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2016-11-28
  • 最后修改日期:2017-02-23
  • 录用日期:
  • 在线发布日期: 2017-07-31